Skip to main content

Table 2 Event rates of study outcomes associated with the use of GLP-1ra versus other glucose-lowering agents

From: Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study

  GLP-1ra (n = 1893) 1:1 matched DPP-4i (n = 1893) GLP-1ra (n = 1829) 1:1 matched SU (n = 1829) GLP-1ra (n = 1367) 1:1 matched insulin (n = 1367)
Composite CVDa
 Number of events 92 141 83 127 78 171
 Total person-years in follow-up 2686.18 3051.80 2669.19 3155.88 1800.99 2595.79
 Crude rate (per 1000 person-years) 34.25 46.20 31.10 40.24 43.31 65.88
All-cause mortality
 Number of events 1 22 2 6 2 30
 Total person-years in follow-up 2755.76 3188.36 2737.90 3275.08 1855.12 2793.32
 Crude rate (per 1000 person-years) 0.36 6.90 0.73 1.83 1.08 10.74
Fatal CVD
 Number of events 1 13 2 3 1 9
 Total person-years in follow-up 2755.76 3188.76 2737.90 3275.21 1855.16 2794.25
 Crude rate (per 1000 person-years) 0.36 4.08 0.73 0.92 0.54 3.22
MACEb
 Number of events 28 59 29 43 21 68
 Total person-years in follow-up 2740.75 3148.35 2721.35 3235.44 1843.70 2722.47
 Crude rate (per 1000 person-years) 10.22 18.74 10.66 13.29 11.39 24.98
  1. CVD cardiovascular disease, DPP-4i dipeptidyl peptidase-4 inhibitor, GLP-1ra glucagon-like peptide-1 receptor agonist, MACE major adverse cardiovascular event, SU sulfonylurea
  2. aComposite CVD was a composite outcome that included acute myocardial infarction, ischemic heart disease, heart failure, stroke, cardiogenic shock, sudden cardiac arrest, arteriosclerotic cardiovascular disease, and arrhythmia
  3. bThree-point MACE included non-fatal myocardial infarction, non-fatal stroke, and death due to cardiovascular diseases